CYCLOCRYOCOAGULATION IN SECONDARY NEOVASCULAR GLAUCOMA AND OUR RESULTS

Area of Science:

• Ophthalmology
• Medical Science

Background:

• Secondary neovascular glaucoma (NVG) is a severe condition often resulting from diabetes or retinal vascular occlusions.
• Effective management of NVG is crucial to prevent vision loss and manage intraocular pressure (IOP).

Purpose of the Study:

• To evaluate the efficacy and outcomes of cyclocryocoagulation (CCK) for secondary neovascular glaucoma.
• To assess changes in intraocular pressure (IOP), visual acuity, pain, and medication requirements post-CCK.

Main Methods:

• A retrospective analysis of 30 CCK procedures performed on 26 eyes of 24 patients between 2016 and 2019.
• Inclusion criteria included NVG secondary to diabetes or retinal vascular occlusion.
• Evaluated parameters included best-corrected visual acuity (BCVA), IOP, pain levels, and antiglaucoma therapy.

Main Results:

• The average patient age was 62 years.
• The most common indications were diabetes (21 procedures) and retinal vascular occlusion (9 procedures).
• The average number of antiglaucoma medication active substances decreased from 3.10 to 2.6 at 6 months post-procedure (p=0.318).

Conclusions:

• Cyclocryocoagulation (CCK) appears to be a viable treatment option for secondary neovascular glaucoma.
• The study suggests a potential reduction in medication burden following CCK treatment for NVG.